<DOC>
	<DOC>NCT00265070</DOC>
	<brief_summary>This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.</brief_summary>
	<brief_title>Trial of Iressa in Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Removal of prostate for prostate cancer Raised level of prostate specific antigen (PSA) postsurgery Can have received some radiation therapy Any after surgery male hormone blocking therapy. Low white blood cell count Abnormal liver function test</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>